NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said on Thursday it has received €2 million ($2.4 million) in financing from funds managed by French private investment firm A Plus Finance.
The funds will go toward the continued development of genetic tests for colorectal cancer and liver cancer, Integragen, also based in France, said, and to accelerate R&D and commercialization efforts directed at molecular diagnostics for autism.
IntegraGen was founded in 2000 and specializes in identifying genetic biomarkers for the development of molecular diagnostics with a focus on autism and oncology. In April, the company launched its Arisk Risk Assessment Test, a genetic screening tool for autism.
Its US affiliate, IntegraGen Inc., is based in Cambridge, Mass.